The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

Arcutis Biotherapeutics has received FDA approval for ZORYVE (roflumilast) topical foam 0.3%, which is now available for treating plaque psoriasis on the scalp and body in patients aged 12 and older.

In this video, Raj Chovatiya, MD, PhD, discusses the latest findings on the use of topical roflumilast in patients with ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

A new King’s College London study links abdominal fat—not general obesity—to increased psoriasis risk, especially in women, ...

A new clinical review explores the complexities of treating psoriasis during pregnancy and lactation highlighting limited ...

Let’s discuss four foods to avoid with psoriasis that may be affecting your skin, along with healthier substitutes.

FDA Approves Topical Foam for Plaque Psoriasis of the Scalp and Body By Lori Solomon HealthDay ReporterTUESDAY, May 27, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved ...